Mabwell (688062.SH), a biopharmaceutical company, announced on Friday that it has received Fast Track Designation (FTD) from the US Food and Drug Administration (FDA) for its self-developed novel Nectin-4-targeting ADC (R&D Code: 9MW2821) intended to treat locally advanced or metastatic Nectin-4 positive triple negative breast cancer (TNBC).
This move is aimed at accelerating the development and review of pharmaceuticals used to treat critical conditions, therefore lowering the time required to bring these drugs to market.
The product has received multiple regulatory designations from the FDA within the last six months. Previously, the product received FTD for the treatment of advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) and recurrent or metastatic cervical cancer (CC) progressed on or subsequent to prior treatment with a platinum-based chemotherapy regimen, and also received Orphan Drug Designation (ODD) for the treatment of esophageal cancer (EC).
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
Kelun-Biotech's SKB518 granted IND clearance by US FDA
Renalytix reports real-world impact of KidneyIntelX on targeted kidney disease treatment
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval